Late-Stage Active Oncology Drug Developers | An Overview
March 9, 2023
Bispecific (bsAbs) & Multispecific antibodies are a diverse family of antibody constructs that recognize two or more epitopes. These candidates...
90 Bi-specific Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
109 Bi-specific Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
In 1986, muromonab-CD3 (OKT3) wins the first therapeutic monoclonal antibody approval from the US FDA, which works as an immunosuppressive...
updated.. easy.. precise... complete...
Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.
LEARN MORE »
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.